Treatment guidelines for chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment, have been in place for many years with new treatment approvals being scarce. Newly approved treatments including Fc-antibody fragment treatments offer potentially safer, more efficacious treatments that could change practice guidelines and improve patient outcomes and satisfy previously unmet needs. Education on historical treatment approaches for CIDP, the burden of disease, the pathophysiology of CIDP and diagnostic challenges, and the emerging biologic treatments is needed for the multidisciplinary healthcare team treating patients with CIDP to improve patient outcomes and raise the standard of care. In this CME Outfitters Snack, expert faculty will address the impact of CIDP and common challenges the multidisciplinary healthcare team faces, including disease burden and pathophysiology, guideline best practices for diagnosis and treatment, and emerging biologic treatments.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/chronic-inflammatory-demyelinating-polyneuropathy-cidp-demystified-from-symptoms-to-solutions/
- Start Date: 2024-11-06 06:00:00
- End Date: 2024-11-06 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Jazz Pharmaceuticals, Inc. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine